EUVIMEDEUVIMED entdecken
Crossref

The anti-dyskinetic effect of the clinic-ready mGluR2 positive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat

Judy Shaqfah iD, Woojin Kang iD, Fleur Gaudette iD, Marianne Khalil, Cynthia Kwan iD, Sébastien Belliveau iD, Élodie Bourgeois-Cayer, Adjia Hamadjida iD, Dominique Bédard, Francis Beaudry iD, Philippe Huot iD

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025

DOI: 10.1007/s00210-024-03627-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Judy Shaqfah und 10 weiteren Autor:innen. Beteiligte Einrichtung: Neurodegenerative Disorders Research Group, Montreal Neurological Institute-Hospital (The Neuro), 3801 University St, Montreal, QC, H3A 2B4, Canada. Hauptthemen laut MEDLINE: Receptors, Metabotropic Glutamate, Dyskinesia, Drug-Induced, Antiparkinson Agents, Parkinsonian Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

L-3,4-dihydroxyphenylalanine (L-DOPA) remains the main treatment for motor symptoms of Parkinson's disease (PD). However, chronic use is associated with the development of complications such as L-DOPA-induced dyskinesia. We previously demonstrated that LY-487,379, a highly selective metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM), reduces the severity of L-DOPA-induced abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD, without interfering with the anti-parkinsonian action of L-DOPA. Here, we seek to determine the effect of AZD8529, another highly selective mGluR2 PAM, on L-DOPA-induced AIMs in the 6-OHDA-lesioned rat. Unlike LY-487,379, AZD8529 has previously undergone clinical trials and could therefore be repurposed if proven efficacious in pre-clinical studies. We first determined the pharmacokinetic (PK) profile of AZD8529 to administer doses leading to clinically relevant plasma levels in the behavioural studies. Then, dyskinetic 6-OHDAlesioned rats were administered AZD8529 (0.1, 0.3, and 1 mg/kg) or vehicle in combination with L-DOPA followed by assessment of AIMs severity. The cylinder test was then used to evaluate the effect of AZD8529 on the anti-parkinsonian action of L-DOPA. We found that AZD8529 (0.1, 0.3 and 1 mg/kg) in combination with L-DOPA significantly reduced the severity of AIMs duration (P < 0.05), but not amplitude, when compared to L-DOPA/vehicle. AZD8529 administration did not interfere with L-DOPA anti-parkinsonian action. Our results provide evidence that mGluR2 positive allosteric modulation with AZD8529 may be a viable, yet relatively modest, treatment strategy to alleviate L-DOPA-induced.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Metabotropic GlutamateDyskinesia, Drug-InducedAntiparkinson AgentsParkinsonian DisordersAnimalsOxidopamineMaleRats, Sprague-DawleyRatsAllosteric RegulationLevodopaDose-Response Relationship, DrugDisease Models, Animal

Stichwörter der Autor:innen

l-DOPA6-OHDA-lesioned ratAZD8529DyskinesiaParkinson’s diseasemGluR2

Substanzen

OxidopamineReceptors, Metabotropic Glutamatemetabotropic glutamate receptor 2Antiparkinson AgentsLevodopa

Autor:innen und Institutionen

  • Neurodegenerative Disorders Research Group, Montreal Neurological Institute-Hospital (The Neuro), 3801 University St, Montreal, QC, H3A 2B4, Canada.
  • Plateforme de Pharmacocinétique, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
  • Département de Biomédecine Vétérinaire, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, QC, Canada.
  • Centre de Recherche sur le Cerveau et l'Apprentissage (CIRCA), Université de Montréal, Montreal, QC, Canada.
  • Neurodegenerative Disorders Research Group, Montreal Neurological Institute-Hospital (The Neuro), 3801 University St, Montreal, QC, H3A 2B4, Canada. philippe.huot@mcgill.ca.
  • Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada. philippe.huot@mcgill.ca.

ORCID-Profile: Judy Shaqfah, Woojin Kang, Fleur Gaudette, Cynthia Kwan, Sébastien Belliveau, Adjia Hamadjida, Francis Beaudry, Philippe Huot

Zitieren

APA

Shaqfah, J., Kang, W., Gaudette, F., Khalil, M., Kwan, C., Belliveau, S., Bourgeois-Cayer, É., Hamadjida, A., Bédard, D., Beaudry, F., & Huot, P. (2025). The anti-dyskinetic effect of the clinic-ready mGluR2 positive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03627-1

Vancouver

Shaqfah J, Kang W, Gaudette F, Khalil M, Kwan C, Belliveau S, et al. The anti-dyskinetic effect of the clinic-ready mGluR2 positive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-024-03627-1

BibTeX
@article{Shaqfah2025,
  author = {Shaqfah, Judy and Kang, Woojin and Gaudette, Fleur and Khalil, Marianne and Kwan, Cynthia and Belliveau, Sébastien and Bourgeois-Cayer, Élodie and Hamadjida, Adjia and Bédard, Dominique and Beaudry, Francis and Huot, Philippe},
  title = {The anti-dyskinetic effect of the clinic-ready mGluR2 positive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  doi = {10.1007/s00210-024-03627-1}
}
Kostenlos starten →